Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021	Dec 31, 2020
Net Income	-5.27	37.92	2.59	-	-
Depreciation & Amortization	21.41	5.28	4.16	-	-
Stock-Based Compensation	19.35	12.93	5.85	-	-
Other Adjustments	-7.57	14.38	26.19	-	-
Change in Receivables	-20.47	-37.49	-18.62	-	-
Changes in Inventories	-7.64	-2.13	-6.55	-	-
Changes in Accounts Payable	28.98	28.84	21.06	-	-
Changes in Accrued Expenses	4.81	5.21	4.21	-	-
Changes in Unearned Revenue	-9.13	-6.23	-3.43	-	-
Changes in Other Operating Activities	-59.07	-3.72	-6.9	-43.12	1.51
Operating Cash Flow	-17.29	27.49	14.27	-43.12	1.51
Operating Cash Flow Growth	-	92.60%	-	-	-
Capital Expenditures	-25.69	-9.12	-6.31	-0.97	-0.19
Purchases of Intangible Assets	-18.08	-13.07	-0.8	-	-0.06
Purchases of Investments	-0.89	-32.91	-8.7	-	-
Payments for Business Acquisitions	-221.36	-20.66	-	-	-0.25
Other Investing Activities	-19.89	-10.93	-1.03	-1.01	-0.34
Investing Cash Flow	-285.92	-86.69	-16.84	-1.98	-0.84
Long-Term Debt Issued	0.53	427.9	4.19	-	-
Long-Term Debt Repaid	0.82	0.75	-	0.25	0.31
Net Long-Term Debt Issued (Repaid)	1.35	428.65	4.19	0.25	0.31
Issuance of Common Stock	1.81	0.66	4.17	2.75	27.07
Net Common Stock Issued (Repurchased)	1.81	0.66	4.17	2.75	27.07
Other Financing Activities	-5.24	-11.03	-1.27	-0.43	-0.49
Financing Cash Flow	-3.72	416.79	7.09	2.07	26.27
Effect of Exchange Rate Changes on Cash and Cash Equivalents	8.8	-1.89	0.99	-	-
Net Cash Flow	-298.13	355.7	5.52	-43.04	26.94
Free Cash Flow	-42.99	18.37	7.97	-44.1	1.32
Free Cash Flow Growth	-	130.64%	-	-	-
FCF Margin	-5.35%	3.56%	2.39%	-798.67%	32.84%
Free Cash Flow Per Share	-0.13	0.05	0.02	-0.16	0.01
Levered Free Cash Flow	-52.1	480.47	14.62	-102.37	-32.94
Unlevered Free Cash Flow	-6.04	67.16	24.09	-98.76	-27.83

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.